Silence Therapeutics plc granted Key European Patent
Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that on 17 January 2018 the European Patent Office granted a further European patent EP 1857547B to Silence.
The allowed claims of European patent EP 1857547B will provide Silence with further protection for its innovative chemical modification technology in Europe. Silence seeks to protect the value of its portfolio and investment, where necessary using all the legal means at its disposal.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:
“These newly granted claims add further value to our intellectual property portfolio, and strengthen our patent position in Europe.”
Download press release here – http://www.silence-therapeutics.com/media/1737/rns-220119-1.pdf